Background: Topical corticosteroids are among the most commonly prescribed skin preparations for the management of a plethora of inflammatory and allergic conditions. Objective: The main aim of this study is to assess the discrepancies in topical corticosteroid prescription patterns and practice recommendations among various healthcare professionals and to identify factors leading to such discrepancies. Methods: The current study is a prospective cross-sectional observational study that was conducted over a period of six months. A validated structured questionnaire was handed out to one hundred community pharmacists working in independent and chain pharmacies with only one pharmacist interviewed per pharmacy store. Prescriptions for topical corticosteroids over a period of six months were reviewed for discrepancies in prescription patterns between general practitioners and dermatologists in one hundred independent and chain community pharmacies included in the study. Results: The most commonly prescribed topical corticosteroid for initial treatment of mild symptoms of atopic dermatitis in children by general practitioners was hydrocortisone acetate (45%), followed by mometasone furoate (33%). In contrast, dermatologists prescribed mostly mometasone furoate (48%), for the aforementioned indications followed by combination products of topical corticosteroid with an antibiotic or an antifungal (22%) for children and adults. On the other hand, Pharmacists mostly recommended an emollient as an initial treatment. Only 14 % of pharmacists interviewed in the study recommended using the fingertip unit to quantify the proper amount of topical corticosteroids. None of the prescribers provided written instructions to patients in fingertip units. Interestingly, only 15% of pharmacists in the study were found to have adequate knowledge about topical corticosteroids use. Adequacy of knowledge was not significantly associated with age of the pharmacist (p value 0.447), gender (p value 0.628), years of experience (p value 0.288), and pharmacy degree (B.SC vs Pharm D, p value 0.444). Conclusion: This study shows that Physician and pharmacist adherence to clinical guidelines for safe prescription of topical corticosteroids was poor. Updating Physicians and pharmacists on practice guidelines is the most urgent recommendation to improve treatment of atopic dermatitis.
INTRODUCTION
Topical corticosteroids are currently placed as first line agents in the management of atopic dermatitis, vitiligo, lichen sclerosus and eczema flare ups and a plethora of inflammatory and allergic skin conditions (1, 2) .
Atopic dermatitis is characterized by periods of remission and acute flares. The choice of a topical corticosteroid for the treatment of inflammatory skin conditions is dependent on steroid potency, disease severity and inflammation site (table 1) . Proactive intermittent therapy with low level topical corticosteroids may help prevent relapse in adolescents and adults (3) (4) (5) (6) (7) . (8) .
Topical corticosteroids are among the most commonly prescribed medications in Jordan. In fact, Jordan is a reasonable representative of topical corticosteroids use in the Middle East and North Africa where most of these preparations can be directly purchased without a prescription. Nonetheless, prescriptions for topical corticosteroids are also common in patients with health insurance coverage and in the more resistant cases of a variety of skin disorders. In this healthcare system, both the physician and the pharmacist are equally responsible for verifying the selection of topical corticosteroids and determining the appropriate use for these agents.
Aim of the study
The main aim of this study is to assess the discrepancies in topical corticosteroid prescription patterns and recommendations among various healthcare professionals and factors leading to such discrepancies. The actual use of topical corticosteroids in Jordan was investigated with an experimental design that takes into consideration the contribution of community pharmacists to the drug usage patterns. In addition, prescription patterns of both general practitioners (GPs) and dermatologists were compared with emphasis on adherence to published practice guidelines. To our knowledge, this is the first study in the region to address the current challenges and set future recommendations pertaining to the use of corticosteroids in a model where both the physician and the pharmacist determine the treatment algorithms. The same study design would be relevant to the evaluation of other classes of drugs in Jordan and other countries in the region with similar healthcare systems.
Materials and Methods
This is a cross-sectional semi-quantitative study in two of the largest cities in Jordan; Amman and Zarqa. The study was commenced in March-2012 and continued for six months. One hundred retail pharmacies were randomly selected and included in the study. In each pharmacy, a staff pharmacist was asked to fill a validated structured questionnaire delivered by hand. In addition, pharmacists were asked to recall all prescriptions pertaining to topical corticosteroids from primary care physicians and dermatologists over a period of six months. The latter served as a means of assessing the prescription patterns for topical corticosteroids. The selected pharmacies were independent and chain pharmacies and represented about 4% of the total number of pharmacies in Jordan.
Content validity of the questionnaire was done by distributing the questionnaire on 15 pharmacies that were not included in the study. A total of 15 pharmacists were recruited in order to complete the validation process. The initial draft of questionnaire was hand delivered to the pharmacists to help finalize the structured questionnaire by eliminating or modifying unnecessary or ambiguous questions.
The final form of the questionnaire consisted of 28 questions that covered three main areas of interest. These areas included: 1) factors influencing pharmacist recommendations, 2) prescription patterns by dermatologists and general practitioners, and 3) pharmacists' knowledge of the published practice guidelines.
Statistical analysis
Data were analyzed using statistical package for social science (SPSS) version 16. Data were presented as frequencies and percentages. Pearson Chi-Square and Fisher's exact test were used to calculate p values for categorical variables.
Results

Demographic characteristics
The demographic details of the pharmacists are shown in table 2. Females accounted for 59% of the pharmacists. About 61% of the pharmacists had more than 5 years of experience. Table 3shows the most commonly prescribed topical corticosteroids, as determined by the prescription records in the pharmacies that participated in the study. The most commonly prescribed topical corticosteroid for initial treatment of mild symptoms of atopic dermatitis in children by general practitioners was hydrocortisone acetate (45%). On the other hand, dermatologists prescribed mostly mometasone furoate (48%). For initial treatment of adults, the most commonly prescribed topical corticosteroid by general practitioners and dermatologists was mometasone furoate (41% vs.38%, respectively). Mometasone furoate was also the most commonly prescribed topical corticosteroid for treatment of disease flare ups in both children and adults (45% and 34%, respectively). Table 4 shows that 60% of pharmacists recognized clobetasolpropionate as the most potent topical corticosteroid of the list of agents provided. On the other hand, only 33% of the pharmacists identified hydrocortisone acetate as the least potent corticosteroid of the list provided.
Prescription patterns of topical corticosteroids
It's common for Jordanian patients to ask pharmacists for their recommendations before seeing a physician. Hence, the questionnaire also assessed practices of pharmacists regarding the proper recommendations for treatment of atopic dermatitis and the use of topical corticosteroids. When pharmacists were asked about their recommendations for treatment of eczema in adults presenting for the first time with mild symptoms; 36% of the pharmacists recommended using an emollient as the treatment of choice while 29% recommended seeing a doctor first. In infants, 44 % of the pharmacists recommended that caregivers should see a doctor first andonly 22% recommended using a topical corticosteroid without consulting a physician.
To assess if the recommendations reflected poor pharmacist knowledge of corticosteroid use and skin flare ups, the participating pharmacists were asked about the topical corticosteroid that they would recommend as a therapeutic equivalent if a prescription forclobetasole (Dermovate ® ) was received and the drug and its other generics were not available (they were informed that the patient will accept this change), 39% recommended betamethasone valerate (a medium potency corticosteroid) as an alternative, and only 15% recommended fluocinonide (same potency class as clobetasol). For patients who complained of no improvement of atopic dermatitis while using a topical corticosteroid for one week, only 6% recommended continuing on the same corticosteroid for a longer period of time.
Pharmacist knowledge of the appropriate dosage forms to be used for different conditions Table 5 shows the pharmacists' knowledge of the dosage forms of topical corticosteroids that should be prescribed according to different skin conditions. Fifty three percent of pharmacists recommended using a cream as the dosage form of choice for mild skin dryness. On the other hand, for severe skin dryness, 59% of pharmacists recommended using an ointment and 33% recommended using a lotion. If symptoms became more severe and bloody or oozing eczema was present, 34% of pharmacists recommended using a gel. 
Pharmacists' knowledge of proper dosage and administration of topical corticosteroids
When pharmacists were asked about their recommendations for the maximum duration of treatment with a very potent topical corticosteroid like clobetasol (assuming that the prescriber doesn't specify the maximum duration of treatment), 36% recommended limiting use for a maximum of one week and 33% of pharmacists recommended a maximum of 3 weeks of daily use. Only 14% of the pharmacists recommended using the fingertip unit to quantify the proper amount of topical corticosteroids. Thirty five and 45% of pharmacists recommended using topical corticosteroids once or twice daily, respectively (table 6) . Interestingly, none of the prescribers provided written instructions to patients in fingertip units. 
Discussion
Most pharmacists participating in the questionnaire had more than 5 years of experience (61%) and carried a bachelor degree in pharmacy (72%). The majority of the pharmacists stated that their recommendations reflected their experience and was largely based on anecdotal evidence. The current study reveals an alarming pattern in community pharmacies in which evidence-based pharmacy practice seems to be largely abandoned. We looked at the two key healthcare professionals that were responsible for defining the current patterns of topical corticosteroids use in Jordan; physicians and pharmacists. The evidence-based practice guidelines that we selected as a basis of the recommendations were those of the American Academy of Dermatology (AAD)/American Academy of Dermatology Association, the British Association of Dermatologists & Primary Care Dermatology Society and the American Academy of Family Physicians (5, 9, 10) . These guidelines comprise the bulk of evidence-based recommendations regarding topical corticosteroids. Interestingly, prescription patterns of topical corticosteroids revealed that there were differences between general practitioners and dermatologists regarding the number and type of topical corticosteroids prescribed for a particular skin condition. This is consistent with what is seen in other countries (11, 12) .
For example, in the USA, prescription patterns of topical corticosteroids showed that dermatologists were 3.9 times more likely to prescribe very high potency corticosteroids than were other physicians. Compared to dermatologists, physicians other than dermatologists were 8.4 times more likely to prescribe combination agents containing moderateor high-potency topical corticosteroids and an anti-infective agent (12) .
Interestingly, in this study, dermatologists prescribed combination products to a greater extent compared to general practitioners. This may simply reflect the fact that dermatologists encounter more severe cases than do general practitioners. The other possibility is that dermatologists are overprescribing the combination products. A third possibility is that dermatologists do not hesitate to prescribe a more potent corticosteroid in children when indicated. In contrast, general practitioners commonly prescribed hydrocortisone acetate, a very low potency corticosteroid, as a first line agent for treatment of eczema in children, regardless of the severity. This pattern is consistent with the guidelines for treatment of atopic dermatitis in children only in cases of mild eczema (4, 6) . Nonetheless, the indiscriminating prescription of hydrocortisone for children with various severities of eczema points to a hesitancy of general practitioners in prescribing more potent corticosteroid. This may reflect a less understanding of the place in therapy and therapeutic properties of the different corticosteroids. On the other hand, mometasone furoate, a moderate potency corticosteroid, was prescribed more often by dermatologists for both children and adults. Prescribing mometasone for treatment of mild symptoms of atopic dermatitis in children is not consistent with the published guidelines since moderate potency corticosteroids like mometasone do not represent a stepwise approach in the treatment and may unnecessarily increase the risk of side effects or skin irritation . (4, 6) Nonetheless, as mentioned above, the current prescription patterns indicate that dermatologists do not hesitate to use more potent corticosteroids even in children.
It should be emphasized, however, that in this region of the world, looking at the prescription patterns alone could result in significant biases in interpreting actual usage patterns of topical corticosteroids. This is due to the fact that topical corticosteroids can be purchased directly without a prescription. For example, in a recent study, prescribing patterns of topical corticosteroids in Bahrain were found to be consistent with published guidelines pertaining to prescribing moderately potent corticosteroids in infants who needed topical corticosteroids (11) . A major limitation to that study, however, was the fact that the pharmacist's contribution to the actual use of topical corticosteroids was not evaluated. Hence, the actual use could not be validated.
The current study establishes a model to study actual drug usage patterns via combining the data of prescription patterns with pharmacist recommendations. Many of the pharmacists interviewed were able to recognize clobetasol as the most potent corticosteroid of the list provided (60%). On the other hand, hydrocortisone acetate, the least potent topical corticosteroid, was recognized by only 33%. Almost half of the pharmacists considered betamethasone valerate as the least potent topical corticosteroid. This observation could be explained by the wide spread recommendations of betamethasone by pharmacists for different indications.
Most of the pharmacists who were interviewed excluded hydrocortisone acetate from being the least potent steroid because they thought that it was produced endogenously in the body.
In this study, only 16% of pharmacists recommended using mometasone furoate, a moderately potent corticosteroid, for treatment of mild symptoms of atopic dermatitis in adults. Sixty five percent of pharmacists did not recommend using topical corticosteroids, possibly due the negative propaganda associated with the use of steroids. Indeed, pharmacists' recommendations for children were more conservative. Seventy eight percent of pharmacists did not recommend using topical corticosteroids.
Most pharmacists were cautious regarding the proper management of disease flares.
In fact, 68% of pharmacists recommended seeing a physician. Only 18 % of pharmacists recommended using a higher potency topical corticosteroid which could be a reasonable option for treatment of disease flares not responding to lower potency agents. On the other hand, seventy two percent of pharmacists recommended seeing a physician if there was no improvement in signs and symptoms within one week of therapy. This indicates that pharmacists were not aware of the delayed effects of topical corticosteroids which involve modification of gene expressions to control the inflammation.
Most of the pharmacists participating in the study were not aware of the correct equivalent potency of topical corticosteroids or how to switch between the different agents. Only 15% of the pharmacists recognized that fluocinonide was an alternative to clobetasol due to comparable potency reflecting poor knowledge of pharmacists of the different potencies of topical corticosteroids. In practice, many drug prescriptions don't specify the exact amount to be used and duration of treatment (11, 14) . Pharmacists were asked about their recommendation for the maximum duration of continued clobetasol treatment if the prescription did not specify the duration. Thirty three percent of pharmacists recommended limiting use for a maximum of three weeks and 36 % recommended limiting duration of treatment to one week. Practice guidelines recommend that highly potent topical corticosteroids should not be used continuously for more than three weeks. The recommended frequency of topical corticosteroids is somewhat controversial. Topical corticosteroids can be used one or more times daily, although no clear benefit has been demonstrated with more than once daily applications (15, 16, 17) . Guidelines recommend limiting the frequency of application of highly potent corticosteroids to once or twice daily. In contrast, hydrocortisone acetate can be used up to four times daily (5, 6, 9) . In this study, eighty percent of pharmacists recommended using topical corticosteroids once or twice daily regardless of corticosteroid potency (35 vs. 45%).Most pharmacists advise patients to apply topical corticosteroids sparingly or thinly. This recommendation creates a state of steroid phobia increasing the risk of poor clinical response and treatment failure (18) . Sixty seven percent of pharmacists participating in the study recommended patients to apply a thin layer of topical corticosteroids to prevent their side effects reflecting poor knowledge in the proper dosing and administration of topical steroids.
To provide effective and safe quantity of topical corticosteroids, the concept of finger-tip unit was developed. One finger-tip unit is a squeeze of cream or ointment along the index finger from the tip to the first finger joint (19) . Only 14% of the pharmacists explained to their patients how to quantify the amount of topical corticosteroids using the finger-tip unit. Finally, for the purpose of assessing adequacy of knowledge, pharmacists who answered 50% or more of the questions pertaining to knowledge correctly were considered to have adequate knowledge. The study shows that only 15% of pharmacists were found to have adequate knowledge reflecting the need for more pharmacists training and continuous education. Adequacy of knowledge was not associated with age, gender, years of experience, and pharmacy degree. These findings strongly points to a gap between current practice guidelines and updates and the actual pharmacy practice in Jordan.
Conclusions
This study provides valuable insights on the prescription patterns and current practices pertaining to the use of topical corticosteroids in the treatment of atopic dermatitis in Jordan. It shows that adherence to guidelines for safe prescription of topical corticosteroids was poor. The study reflects the poor knowledge of pharmacists of the correct practices for the use of topical corticosteroids in general and in treatment of atopic dermatitis in particular. In addition, the study shows distinct differences between the prescription patterns of topical corticosteroids between general practitioners and dermatologists.
The study unravels a great opportunity to improve the clinical outcomes in patients on topical corticosteroids therapy. Updating pharmacists and general practitioners on practice guidelines is the most urgent recommendation to improve treatment of atopic dermatitis.
